Show simple item record

dc.contributor.authorvan Diessen, DJ
dc.contributor.authorDe Ruysscher, D
dc.contributor.authorSonke, JJ
dc.contributor.authorDamen, E
dc.contributor.authorSikorska, K
dc.contributor.authorReymen, B
dc.contributor.authorvan Elmpt, W
dc.contributor.authorWestman, G
dc.contributor.authorFredberg, PG
dc.contributor.authorDieleman, E
dc.contributor.authorBjorkestrand, H
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorBelderbos, J
dc.date.accessioned2018-12-05T10:35:49Z
dc.date.available2018-12-05T10:35:49Z
dc.date.issued2018en
dc.identifier.citationvan Diessen J, De Ruysscher D, Sonke J-J, Damen E, Sikorska K, Reymen B, et al. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiotherapy and Oncology. 2018 Oct.en
dc.identifier.pmid30327236en
dc.identifier.doi10.1016/j.radonc.2018.09.019en
dc.identifier.urihttp://hdl.handle.net/10541/621355
dc.description.abstractBACKGROUND AND PURPOSE: The PET-boost randomized phase II trial (NCT01024829) investigated dose-escalation to the entire primary tumour or redistributed to regions of high pre-treatment FDG-uptake in inoperable non-small cell lung cancer (NSCLC) patients. We present a toxicity analysis of the 107 patients randomized in the study. MATERIALS AND METHODS: Patients with stage II-III NSCLC were treated with an isotoxic integrated boost of ?72?Gy in 24 fractions, with/without chemotherapy and strict dose limits. Toxicity was scored until death according to the CTCAEv3.0. RESULTS: 77 (72%) patients were treated with concurrent chemoradiotherapy. Acute and late ?G3 occurred in 41% and 25%. For concurrent (C) and sequential or radiotherapy alone (S), the most common acute ?G3 toxicities were: dysphagia in 14.3% (C) and 3.3% (S), dyspnoea in 2.6% (C) and 6.7% (S), pneumonitis in 0% (C) and 6.7% (S), cardiac toxicity in 6.5% (C) and 3.3% (S). Seventeen patients died of which in 13 patients a possible relation to treatment could not be excluded. In 10 of these 13 patients progressive disease was scored. Fatal pulmonary haemorrhages and oesophageal fistulae were observed in 9 patients. CONCLUSION: Personalized dose-escalation in inoperable NSCLC patients results in higher acute and late toxicity compared to conventional chemoradiotherapy. The toxicity, however, was within the boundaries of the pre-defined stopping rules.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.radonc.2018.09.019en
dc.titleThe acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlandsen
dc.identifier.journalRadiother Oncolen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record